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Abstract
Background: Langerhans cell histiocytosis (LCH) is a rare disease that affects mainly young children, and which features
granulomas containing Langerhans-type dendritic cells. The role of several human herpesviruses (HHV) in the pathogenesis
of LCH was suggested by numerous reports but remains debated. Epstein-barr virus (EBV, HHV-4), & Cytomegalovirus (CMV,
HHV-5) can infect Langerhans cells, and EBV, CMV and HHV-6 have been proposed to be associated with LCH based on the
detection of these viruses in clinical samples.
Methodology: We have investigated the prevalence of EBV, CMV and HHV-6 infection, the characters of antibody response
and the plasma viral load in a cohort of 83 patients and 236 age-matched controls, and the presence and cellular
localization of the viruses in LCH tissue samples from 19 patients.
Principal Findings: The results show that prevalence, serological titers, and viral load for EBV, CMV and HHV-6 did not differ
between patients and controls. EBV was found by PCR in tumoral sample from 3/19 patients, however, EBV small RNAs
EBERs –when positive-, were detected by in situ double staining in bystander B CD20
+ CD79a
+ lymphocytes and not in
CD1a
+ LC. HHV-6 genome was detected in the biopsies of 5/19 patients with low copy number and viral Ag could not be
detected in biopsies. CMV was not detected by PCR in this series.
Conclusions/Significance: Therefore, our findings do not support the hypothesis of a role of EBV, CMV, or HHV-6 in the
pathogenesis of LCH, and indicate that the frequent detection of Epstein-barr virus (EBV) in Langerhans cell histiocytosis is
accounted for by the infection of bystander B lymphocytes in LCH granuloma. The latter observation can be attributed to
the immunosuppressive micro environment found in LCH granuloma.
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Introduction
Langerhans cell histiocytosis (LCH, a.k.a. histiocytosis X), is a
rare disease that affects mainly young children, and features
granulomas consisting of Langerhans-like cells (LC), mixed with
macrophages, eosinophiles, multinucleated giant cells, and lym-
phocytes, that can be found within various tissues [1,2].
The presence of LC in granuloma is a key diagnostic feature of
LCH. LC are members of the dendritic cell (DC) family, that
trigger and shape immune responses, and the pathophysiology of
LCH is likely to involve immune mechanisms (reviewed in [3,4]).
We have previously reported that LC found in LCH granuloma
were phenotypically and functionally immature/semi-mature LC
[5]. Immature/semi-mature DCs are believed to be prone to
induce regulatory T cells, that inhibit polyclonal T cell responses
and promote tolerance [6,7,8,9]. The accumulation of immature
LC in LCH granulomas was associated with the expansion of
FoxP3
+ CD25 + CD4
+ regulatory T cells both in granuloma and
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immunosuppression, which favors reactivation of herpes-virus
infection, may be a feature of LCH.
Environmental agents and viruses, in particular Epstein-Barr
virus (EBV), or vaccination, have been proposed to trigger, or to
play a role in the pathogenesis of the disease [11,12].
Herpesviruses are DNA viruses responsible for persistent infection.
EBV is the etiological agent of several malignancies [13,14], and
EBV & Cytomegalovirus (CMV) are responsible for hemophago-
cytic syndromes in human with several inherited immunodefi-
ciencies [15,16]. EBV has been reported to infect monocytes and
Langerhans cells (LC), during the natural course of infection in
human [17,18]. Infection with EBV has been reported to be
associated with LCH, to represent a possible etiology, and/or to
contribute to its pathophysiology in some studies [11,12,19].
However, other studies failed to replicate these findings, and the
possible causative role of EBV in LCH is debated [20,21,22].
CMV can also infect DC and LC [23,24,25], and one single study
reported CMV detection in lesional LC in one third of 29 patients
by immunohistochemistry, in situ hybridization, and PCR [26].
HHV-6 infects mainly T cells, but is also reported to infect
myeloid cells [27,28] and HHV-6 DNA or immunoreactivity was
detected in lesions of 50% to 75% of patient with LCH [29,30],
however, control studies performed by the same group concluded
that the prevalence of HHV-6 in the tissue of LCH patients is the
same as that found in tissue from individuals without disease [31].
Sero-epidemiological studies have been useful to demonstrate
the role of EBV in Burkitt lymphoma and Hodgkin disease, when
high antibody titers to EBV structural antigens (VCA) have been
associated to the risk of developing Burkitt’s lymphoma and
Hodgkin diseases [32,33]. However, to our knowledge no sero-
epidemiological study have been conducted in LCH. The present
study was therefore designed to investigate the role of EBV, CMV,
and HHV-6 using two methods. First, we performed a case-
controlled sero-epidemiological study to investigate a relationship
between the onset of LCH in young children and the antibody
response to infection with EBV, CMV, or HHV-6, and second we
searched for the presence of viruses in the serum of patients, and in
Langerhans cells in tumor samples, by PCR and, when positive,
we investigated the cellular target of the viruses by immunolabel-
ing and in situ hybridization. Results ruled out an epidemiological
association between these herpes-virus and LCH.
Results
Prevalence of EBV, CMV, and HHV-6 infection as a function
of age and of clinical presentation of disease. The presence of
antibodies against EBV, CMV and HHV-6 was investigated by
ELISA in the serum of 78 children diagnosed with LCH and 206
age matched controls. To avoid contamination by maternal IgG,
only children six month-old and older where studied for the
presence of specific antibodies in serum. Twenty six children with
LCH (33.3%) and 94 controls (47.1%) tested seropositive for EBV.
No significant difference was observed between patient and
control groups when matched for age (Table 1). Similarly, no
significant difference was observed with the control group when
patients were grouped by disease stage/clinical presentation
(Table 2). Similar results were observed for CMV and HHV-6,
and the prevalence of both infections in children with LCH were
comparable to their prevalence among age-matched controls
(Tables 2,and 3).
Serum IgG titers directed against EBV, as well as CMV and
HHV-6, did not differ between patients and controls. Titers of
EBV antibodies have been shown to differ from controls in several
diseases linked to EBV [14,34]. IgG VCA titers, and in some cases
anti-Epstein-Barr nuclear antigen (EBNA)1 antibody, are consis-
tently higher in patients with nasopharynx carcinoma or Hodgkin
disease than in control populations [14]. Lower EBNA1-IgG
antibody titer is also considered as a possible serological sign for a
defective control of the persistent latent EBV carrier state. In the
present study, both VCA IgG and EBNA IgG titers were found to
be similar in patients with LCH in comparison with controls, when
matched for age, or when grouped by disease stage/clinical
presentation (Figure 1A–E). Anti HHV-6 or anti CMV IgG titers
were also not different between patients and the control group
(data not shown)
Prevalence of detectable serum viral load for EBV, CMV, and
HHV-6. Defective control of infection by Herpesviruses such as
EBV, CMV and HHV-6 ultimately results in replicative infection
and viremia [35]. Serum viral load during CMV infection is a
sensitive technique, but in the present study, out of 83 patients and
236 age-matched controls, 0% of patient and 3% of controls
(n=7) had detectable CMV serum viral load (table 4) indicating
Table 1. Prevalence of EBV, CMV, and HHV-6 infection in LCH
patients
Controls LCH total LCH1 LCH2 LCH3
EBV
Non-infected n 109 52 28 12 12
% 52.9 66.7 65.1 63.2 75
Infected n 97 26 15 7 4
% 41.1 33.3 34.9 36.8 25
Total n 206 78 43 19 16
% 100 100 100 100 100
Test Fisher’s exact 0.475
CMV
Non-infected n 131 58 32 13 13
% 64.2 75.3 76.2 68.4 81.2
Infected n 72 18 9 6 3
% 35.3 23.4 21.4 31.6 18.8
Unknown* n 1 1 1 0 0
% 0.5 1.3 2.4 0 0
Total n 204 77 42 19 16
% 100 100 100 100 100
Test Fisher’s exact 0.282
HHV-6
Non-infected n 33 15 5 5 5
% 1.4 19.5 11.9 26.3 31.2
Infected n 161 62 37 14 11
% 80.1 80.5 88.1 7.7 68.7
Unknown* n 7 0 0 0 0
% 3 . 5 0 000
Total n 201 77 42 19 16
% 100 100 100 100 100
Test Fisher’s exact 0.424
Unknown
*: IgG value are in the ‘grey zone’ (see methods)
LCH1: single system, no risk organs
LCH2: multisystem, no risk organs
LCH3: risk organs
doi:10.1371/journal.pone.0003262.t001
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EBV infection is considered to be less sensitive than during CMV
infection [36], nevertheless we found that only 1.2% of patients
(n=1) and a similar percentage (0.9% of controls, n=2) had a
detectable EBV viral load in serum (Table 4). These results are
consistent with anti-VCA IgG titers, which were found similar in
Table 2. Prevalence of EBV, CMV, and HHV-6 infection as a function of age
Age 0.5 to 5 Age 5 to 10 Age 10 to 20
Controls LCH Controls LCH Controls LCH
EBV
Non-infected n 79 35 19 11 11 6
% 71.8 85.4 35.8 45.8 25.6 46.1
Infected n 31 6 34 13 32 7
% 28.2 14.6 64.1 54.2 74.4 53.8
Total n 110 41 53 24 43 13
% 100 100 100 100 100 100
Test Fisher’s exact 0.093 0.577 0.378
CMV
Non-infected n 74 34 29 13 27 11
% 69.4 85 54.7 54.2 62.8 84.6
Infected n 33 6 23 10 16 2
% 30.6 15 43.4 41.7 37.2 15.4
Unknown* n 0 0 1 1 0 0
% 0 0 1.9 4.2 0 0
Total n 107 40 53 24 43 13
% 100 100 100 100 100 100
Test Fisher’s exact 0.062 0.82 0.186
HHV-6
Non-infected n 18 14 5 0 10 1
% 17 35 9.4 0 23.8 7.7
Infected n 84 26 47 24 30 12
% 79.2 65 88.7 100 71.4 92.3
Unknown* n 4 0 1 0 2 0
% 3.8 0 1.9 0 4.8 0
Total n 106 40 53 24 42 13
% 100 100 100 100 100 100
Test Fisher’s exact 0.037 0.217 0.356
doi:10.1371/journal.pone.0003262.t002
Table 3. Prevalence of HHV-6 infection in children before the age of 5 years
Age 0.5 to 1 Age 1 to 1.5 Age 1.5 to 2 Age 2 to 5
controls LCH controls LCH controls LCH controls LCH
Non-infected n 5 8 0 2 4 0 9 4
% 35.7 66.7 0 33.3 30.8 0 14.8 21
Infected n 9 4 17 4 9 3 49 15
% 64.3 33.3 95.4 66.7 69.2 100 80.3 79
Unknown* n 0 0 1 0 0 0 3 0
% 0 0 5.6 0 0 0 4.9 0
Total n 14 12 18 6 13 3 61 19
% 100 100 100 100 100 100 100 100
Test Fisher’s exact 0.238 0.054 0.529 0.663
doi:10.1371/journal.pone.0003262.t003
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to be correlated with anti-VCA IgG titer [34]. The significance of
the detection of HHV-6 in the serum is still discussed [37,38], but
again only 3.6% of patients (n=3) and 2.5% of controls (n=6) had
a detectable HHV-6 serum viral load, and there was no difference
between groups as per fischer exact’s test (Table 4).
Detection of EBV, CMV, and HHV-6 DNA in biopsy samples
from LCH granuloma. We then investigated whether Herpesvi-
ruses were present in LCH granuloma, in the absence of overt
viremia. As shown in table 5, EBV DNA was found in 15% of
biopsy samples examined (3/19 patients, #1, 9, & 15), and HHV-
6 DNA in 26% of biopsy samples examined (5/19 patients). CMV
DNA was not detected in this series. EBV and HHV-6 viral loads
were low with a median of 400 copies/10
6 cells except for patient
#5. Patient #5 display a very high HHV-6 load in the biopsy and
in the blood over time (data not shown) compatible with the
detection of a chromosomally integrated HHV-6 DNA [39].
Therefore, our data support previous results showing the
presence of EBV or HHV-6 in a subset of LCH granuloma.
However, since HHV-6 and EBV are responsible for persistent
infection of T cells and B cells respectively, the detection of virus
DNA in LCH samples could be attributed to infection of bystander
cells [21].
We therefore investigated whether EBV infects bystanders
lymphocytes, macrophages, and Langerhans cells in samples from
patients #1, 9, & 15, which tested positive by PCR, using in situ
hybridisation with a probe against EBV EBERs RNA on paraffin
sections of LCH granuloma, followed by immunohistochemistry
with antibodies against B-cells (CD20 & CD79a), T-cells (CD3),
macrophages (CD68), or Langerhans cell (CD1a) antigens on the
same tissue sections. EBV positive cells were always found in areas
rich in B cells, and were labeled with either CD20, or CD79a
antibodies (Figure 2), while no EBER+ cell labelled with CD1a,
CD3, or CD68 cell was observed. These data indicate that EBV
infects bystander B cells, which are present in a subsets of LCH
granuloma [12]. Although positive controls were obtained, we did
not observed immunoreactivity against HHV-6 in samples positive
for HHV-6 DNA by PCR (data not shown), therefore the cellular
target of HHV6 in LCH granuloma was not identified.
Discussion
The present study is the largest case-controlled sero-epidemi-
ological study performed in this disease. The results argue against
an epidemiological association between LCH and EBV, CMV, or
HHV-6 infection.
Further investigation of the cellular localization of the viruses in
LCH tissue samples from 19 patients indicated that, when present,
EBV infected bystander lymphocytes and not Langerhans cells.
We think that our results therefore resolve the much debated issue
of the role of EBV in the pathogenesis of LCH [19,21,22,30,31].
Because EBV infected B cells are present in the blood of healthy
Figure 1. VCA-IgG and EBNA-IgG titers (UA/ml) in patients and controls with past EBV infection. VCA-IgG (A, B, C) and EBNA-IgG titers (D,
E, F) (UA/ml) were determined as indicated in methods, and patients were compared to controls without stratification (A, D), and after stratification
based on age (B, E), or disease extension (C, F).
doi:10.1371/journal.pone.0003262.g001
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6
[41] it is not unexpected to find a small number of EBV infected B
cells in LCH granuloma, which contains B cells. In addition,
because the growth of EBV infected B cells is under the control of
CD8 cytotoxic T cells in healthy individuals [42], the regulatory T
cell-rich environment of the LCH granuloma [10], may represent
a sanctuary for such EBV infected B cells.
Anti CMV IgG titers in patients and controls, and absence of
detection of the virus by PCR in the serum and in biopsy samples
strongly suggest that CMV is not associated with LCH.
The case of HHV6 is more complicated. HHV-6 was detected
by PCR in the serum of 3.8% of patients and 2.5% of controls with
viral loads above 10
4 copies/ml in 5 out of 9 detected (data not
shown). The prevalence of HHV-6 in patients and controls were
similar to the reported prevalence of chromosomally integrated
HHV6 among blood donors [39]. Therefore HHV6 detection
may be related to the presence of chromosomally integrated
HHV-6. HHV6 DNA was also detected by PCR in biopsies from
5/19 patients (26%), suggesting that HHV6, like EBV can be
found in LCH granuloma. However the viral load was very low,
and the virus was not detectable by immunochemistry suggesting
that HHV-6 infection is quiescent. Together with our serological
data and serum PCR, and in the light of the study of Glotzbecker
et al, [31] who found a similar frequency PCR positive samples in
LCH granuloma and control tissues, we hypothetize that HHV6
do not productivey infect LC in vivo and may be carried by
bystander lymphocytes which are present in the granuloma.
Our study did not identify a subset of patients with ‘herpes-
viruses associated’ LCH. We did not found an association between
EBV, CMV, or HHV-6 infection and patients when they were
stratified by age, or by clinical stage.
Among other herpes viruses, HHV-1 (HSV-1), HHV-2 (HSV-
2), HHV-3 (VZV) and HHV-7 infections were never reported to
be associated with LCH, and were not investigated in this study.
Among herpesviruses, HHV-8 has been initially reported to infect
dendritic cells, but several studies have excluded its association
with LCH [43,44].
Methods
Patients & controls
The diagnostic and inclusion criteria as well as the definition of
the organs involvement for the French nationwide LCH survey
have been described elsewhere [2]. Briefly, the extension of the
diseases has been classified in three groups according to histiocyte
society criteria: group 1: single organ extension, without risk
organs group 2 mulsystem organ without risk organs and group 3
patients with risk organs i.e. lung and/or liver and/or spleen and/
or hematological dysfunction. According to French bioethics laws,
informed consent was signed if the patients participated and the
database was approved by the French computer watchdog
commission (CNIL certificate nu 99.087). Clinical information,
radiological findings and extension were recorded, together with
treatments received. Data monitoring, based on medical charts,
was done by a clinical research associate who visited each center.
Involvement of at least one new organ, as described elsewhere 2,
Table 4. Prevalence of detectable serum viral load for EBV,
CMV, and HHV-6
Patients Controls Total
EBV
Negative 82 234 316
% 98.8 99.1 99.1
Positive 1 2 3
% 1.2 0.9 0.9
Total 83 236 319
% 100 100 100
Fisher’s exact=1.000
1-sided Fisher’s exact=0.596
CMV
Negative 83 229 312
% 100 97. 97.8
Positive 0 7 7
% 0 3 2.2
Total 83 236 319
% 100 100 100
Fisher’s exact=0.197
1-sided Fisher’s exact=0.118
HHV-6
Negative 80 230 310
% 96.4 97.5 97.2
Positive 3 6 9
% 3.6 2.5 2.8
Total 83 236 319
% 100 100 100
Fisher’s exact=0.701
1-sided Fisher’s exact=0.428
doi:10.1371/journal.pone.0003262.t004
Table 5. Detection of EBV, CMV, and HHV-6 DNA in biopsy
samples from LCH granuloma.
Patient stage sex HHV-6 EBV CMV
1 LCH1 F - 6 10
3 -
2 LCH1 M 8 10
2 --
3 LCH1 M - - -
4 LCH1 F 6 10
1 --
5 LCH1 M 2 10
6 --
6 LCH1 F - - -
7 LCH1 M - - -
8 LCH1 F - - -
9 LCH1 F - 1.7 10
5 -
10 LCH1 F - - -
11 LCH1 M - - -
12 LCH1 M - - -
13 LCH1 M - - -
14 LCH1 F - - -
15 LCH1 M - 4 10
2 -
16 LCH2 M 4 10
2 --
17 LCH3 M - - -
18 LCH3 M - - -
19 LCH3 M 4 10
2 --
Positive results are expressed as the number of viral genome copies per million
cells.
doi:10.1371/journal.pone.0003262.t005
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PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3262Figure 2. Detection of EBV-infected B cells by in situ hybridization combined with immunohistochemistry. Granuloma serial sections
were stained for CD1a (upper left) or for CD20 (middle left) by immunohistochemistry or for EBERs by in situ hybridisation (upper right, arrows
indicate EBER positive cells). Combined detection of CD20 or CD79a with EBERs shows that EBV-infected cells are B cells (arrows).
doi:10.1371/journal.pone.0003262.g002
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obtained, after written witnessed informed consent was obtained
from the parents of all patients, from 83 pediatric patients with
LCH included in the French LCH registry, following a research
protocol approved by the ethics committee of the Nantes
University Hospital (France, EU). Biopsies samples were also
obtained from 19 patients with LCH included in the French LCH
registry after written witnessed informed consent was obtained.
Control serum samples were obtained from the children admitted
to the outpatient unit of the Grenoble University Hospital (France,
EU), according to institutional guidelines, and were matched for
age with patient samples for statistical analysis.
Serology
Qualitative and quantitative analysis of specific Ig against EBV,
CMV and HHV-6 were performed on serum samples from 83
patients and 235 controls using microplate ELISA kits: IgG anti-
VCA (ETI-VCA-G, DiaSorinH), IgG anti-EBNA (ETI-EBNA-G,
DiaSorinH), IgM anti-VCA (DiaSorinH,ETI-EBV-M), IgG anti-
CMV(ETI-CYTOK-G PLUS, DiaSorinH) and IgG anti-HHV-6
(HHV-6 IgG EIA, BiotrinH). Patients and controls were classified
in three categories according to the detection of specific IgG i/
above the upper limit of the grey zone for ‘‘infected’’ status, ii/in
the grey zone for ‘‘unknown’’ status, iii/below the lower limit of
the grey zone for ‘‘uninfected’’ status.
DNA extraction from frozen biopsies and serum
DNA was extracted from sliced frozen biopsies using ALLPrep
DNA/RNA minikit (Qiagen, Hilden, Germany). Total DNA was
eluted with 200 ul of water and amplification of the beta-globin
gene by real time PCR was used to evaluate total cell number per
sample (Beta-globine PCR Kit, Roche DiagnosticsH). DNA was
extracted from 200ul of serum using Blood DNA mini kit and
eluted in a volume of 100ul.
Quantitative PCR for the detection of EBV, CMV and HHV-
6
ten ul of DNA extract were used to detect and quantify viral
genomes by real time PCR assays. All positive PCR were run a
second time for confirmation.
EBV tyrosine kinase gene (TK) was amplified from biopsies DNA
with T1 (59-GGGGCAAAATACTGTGTTAG-39)+T2 (59-CGG-
GGGACACCATAGT-39) primers and LC1 (59-ATGTTTC-
CTCCCTCGCTTCTTCAG-fluo-39)+LC2 (59-ATGTTTCCT-
CCCTCGCTTCTTCAG-fluo-39) probes. PCR were run on a
Light Cycler. The EBV-negative DG75 cell line was used as a
negative control. The EBV-positive Burkitt’s lymphoma cell line
‘‘Namalwa’’[45]harboring2copiesofviralgenomepercellisusedas
a standard for quantification. Detection limit is 2 copies of viral
genome per amplification [46].
CMV immediate early-1 gene (IE1) was amplified using forward
59-GCAGACTCTCAGAGGAT-39+reverse 59-AGCGCCG-
CATTGAGGA-39 primers and a 6-carboxyfluoresceine (FAM) -
59 ATCTGCATGAAGGTCTTTGCCCAGTACATT-39 car-
boxytetramethyl rhodamine (TAMRA) probe. PCR were run on
a ABI 7300 real time PCR system (Applied Biosystem).Quantifica-
tion was obtained using a plasmid and the detection limit is 20
copies of viral genome per amplification [35].
HHV-6 U65-U66 gene was amplified using forward 59-
GACAATCACATGCCTGGATAATG-39+reverse 59-TGTAAG-
CGTGTGGTAATGGACTAA -39 primers and a 6-carboxyfluor-
esceine (FAM) -59 AGCAGCTGGCGAAAAGTGCTGTGC-39
carboxytetramethyl rhodamine (TAMRA) probe. PCR were run
on a ABI 7300 real time PCR system (Applied Biosystem).Quanti-
fication was obtained using a plasmid and detection limit is 25 copies
of viral genome per amplification [47].
PCR results were expressed as the number of viral genome
copies per million cells for biopsies and as the number of viral
genome copies per ml of serum from peripheral blood.
In situ hybridization & immunohistochemistry
Detection of EBV EBERs RNA by in situ hybridization was
performed first and was followed by immunohistochemistry with
antibodies against B-cell, T-cell and Langerhans cell antigens. Five
micrometers paraffin-embedded sections were mounted onto glass
slides and pretreated in 0.4% pepsine HCl 0.2M, then hybridized
with EBER PNA probes (DAKO), following the manufacturer’s
instructions, and revealed with NBT/BCIP after APAAP ampli-
fication. Immunohistochemistry was then performed using a
streptavidin-biotin peroxidase method (LSAB2, DAKO) after
microwave heating, revealed with AEC or DAB. Antibodies used
were directed against the following antigens : CD20 (L26, 1:200,
Dako,), CD79a (JCB117, 1:50, Dako), CD3 (UCHT1, 1:50 Dako),
CD1a (MTB1, 1:25,Novocastra), CD68 (KP1, 1:200, Dako).
Statistical methods
Stata SoftwareH version 8 was used for all statistical analyses.
Categorical data were compared by using Fisher’s exact test, and
quantitative data (titer if seropositivity) by using Kruskal-Wallis
non parametric test. All tests were two-tailed. P values of less than
0.05 were considered to indicate statistical significance unless
otherwise stated.
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